By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alnylam Pharmaceuticals 

300 Third Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-551-8200 Fax: 617-551-8101


SEARCH JOBS

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease.

The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.


Key Statistics


Email: info@alnylam.com
Ownership: Public

Web Site: Alnylam Pharmaceuticals
Employees:
Symbol: ALNY
 



Industry
Biotechnology


Collaborations

Cubist Pharmaceuticals, Inc. 





Company News
Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length 8/27/2014 10:38:41 AM
Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating Double-Stranded Molecules Comprising Up To 25 Base Pairs 8/20/2014 8:36:55 AM
Alnylam Pharmaceuticals (ALNY) Reports Second Quarter 2014 Financial Results And Highlights Recent Period Activities 8/8/2014 9:08:37 AM
Alnylam Pharmaceuticals (ALNY) Receives Orphan Drug Designations In The European Union For ALN-AT3, An Rnai Therapeutic In Development For The Treatment Of Hemophilia 8/7/2014 10:35:48 AM
Alnylam Pharmaceuticals (ALNY) To Webcast Conference Call Discussing Second Quarter 2014 Financial Results 8/1/2014 8:55:45 AM
Alnylam Pharmaceuticals (ALNY) To Host Additional Events In "RNAi Roundtable" Webcast Series 7/29/2014 9:53:03 AM
Alnylam Pharmaceuticals (ALNY) To Host Additional Events In “RNAi Roundtable” Webcast Series 7/29/2014 9:43:48 AM
Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Conjugate-Based Delivery Of RNA Therapeutics 7/22/2014 11:02:15 AM
Alnylam Pharmaceuticals (ALNY) Elects Amy Schulman To Its Board Of Directors 7/2/2014 9:41:54 AM
Alnylam Pharmaceuticals (ALNY) Added To Russell 1000 Index As A Member Of The Large-Cap Segment Of The U.S. Equity Universe 6/30/2014 10:33:00 AM
12345678910...
//-->